Kunal Sangal, MD
Interventional Cardiology · Tulsa, OKNPI 1679910350
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,446 of the $8,314 with a category attached, or 77.5%. It is spread thinly across 28 manufacturers, the largest accounting for just 17.6% — the pattern of someone who eats at a lot of different presentations.
Across 127 payments — averaging $65.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$1K
- Abiomed$1K
- Edwards Lifesciences$1K
- Abbott$1K
- Boston Scientific$921
- Penumbra, Inc.$391
- plus $2K from 22 others
What the payments were for
- Travel & lodging$1,55919%
- Food & beverage$6,44678%
- Education$3084%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 12 | $1,464 |
| Abiomed | 25 | $1,416 |
| Edwards Lifesciences | 11 | $1,229 |
| Abbott | 16 | $1,085 |
| Boston Scientific | 9 | $921 |
| Penumbra, Inc. | 3 | $391 |
| Philips North America LLC | 6 | $345 |
| AstraZeneca | 5 | $183 |
| Shockwave Medical, Inc | 1 | $171 |
| Chiesi USA, Inc. | 2 | $146 |
| Asahi Intecc USA, Inc. | 2 | $125 |
| Cardiovascular Systems Inc. | 1 | $124 |
| W. L. Gore & Associates, Inc. | 2 | $95 |
| Amgen | 6 | $94 |
| Inari Medical, Inc. | 4 | $84 |
| Novo Nordisk | 3 | $65 |
| E.r. Squibb & Sons, L.L.C. | 3 | $54 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $46 |
| Cvrx, Inc. | 2 | $46 |
| Stryker | 1 | $43 |
| Johnson & Johnson | 2 | $41 |
| Angiodynamics, Inc. | 2 | $39 |
| Irhythm Technologies, Inc. | 1 | $24 |
| Baxter Healthcare | 1 | $20 |
| Novartis | 1 | $18 |
| Pfizer | 1 | $16 |
| Daiichi Sankyo Inc. | 1 | $16 |
| Lantheus Medical Imaging, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- COREVALVE EVOLUT R$798
- Impella$608
- Indigo System$254
- GENERAL - STRUCTURAL HEART$231
- Ensite Cardiac Mapping System$209
- CoreValve Evolut$206
- Optis Coronary Imaging System$203
- GENERAL VASCULAR ACCESS$186
- GENERAL - STENTS$175
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$171
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$139
- Penumbra System$138
- KENGREAL$132
- Diamondback Coronary$124
- ASAHI PTCA Guide Wire$112
- MitraClip$110
- MitraClip System$108
- OPTIS$104
- General - Balloon Catheters$103
- Resolute$100
How this compares
$8,314 in reported general payments places this provider in the 55th percentile of 110 interventional cardiology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 150 | $152,213 |
| XareltoRivaroxaban | 50 | $42,042 |
| JardianceEmpagliflozin | 18 | $25,624 |
| EntrestoSacubitril/Valsartan | 24 | $20,237 |
| Repatha SureclickEvolocumab | 14 | $14,212 |
| NexletolBempedoic Acid | 12 | $4,673 |
| Metoprolol Succinate | 236 | $3,403 |
| ClopidogrelClopidogrel Bisulfate | 112 | $3,027 |
| Rosuvastatin Calcium | 72 | $2,226 |
| Atorvastatin Calcium | 90 | $1,674 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 109 | $1,440 |
| Amlodipine Besylate | 162 | $1,188 |
| Ranolazine ErRanolazine | 16 | $1,140 |
| Losartan Potassium | 111 | $1,094 |
| Carvedilol | 95 | $1,062 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $16 | $152,213150 claims |
| Johnson & JohnsonXarelto | $41 | $42,04250 claims |
| NovartisEntresto | $18 | $20,23724 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 110 interventional cardiology providers in Oklahoma.
Other interventional cardiology in Tulsa
- Kamran MuhammadTulsa$1.4M
- Stanley ZimmermanTulsa$93K
- Matthew ComstockTulsa$69K
- Wayne LeimbachTulsa$68K
- Tom HuTulsa$57K
- Eugene IchinoseTulsa$49K
- Poorya FazelTulsa$29K
- Tucker HarrisonTulsa$19K
- Andrew KurklinskyTulsa$15K
- Stewart KatzTulsa$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.